TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc., trading on Nasdaq under the ticker MTAC, is a medical technology company that completed its business combination with MedTech Acquisition Corp in late 2022, following the SPAC's initial public offering in 2021. The blank-check vehicle was sponsored by MedTech Acquisition Sponsor LLC and targeted the healthcare and medical device sector. TriSalus develops the TriNav Infusion System, a pressure-enabled drug delivery platform designed to improve liver-directed cancer therapy, positioning the company within the oncology medical device space. The company filed an 8-K with the SEC on August 15, 2024, under accession number 0001104659-24-089936. For comprehensive data on TriSalus Life Sciences, its SPAC history, and related filings, create a free account on SpacDesk.